+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Haegarda"

From
Plasma Protease C1-Inhibitor Global Market Report 2025 - Product Thumbnail Image

Plasma Protease C1-Inhibitor Global Market Report 2025

  • Report
  • July 2025
  • 175 Pages
  • Global
From
From
Hereditary Angioedema Market Report and Forecast 2025-2034 - Product Thumbnail Image

Hereditary Angioedema Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Haegarda is a market of drugs used to treat immune disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, and autoimmune diseases. They work by suppressing the body's immune response, which can help reduce inflammation and other symptoms associated with these conditions. Haegarda drugs are typically administered through injections or inhalers, and can be used to treat both acute and chronic conditions. The Haegarda market is highly competitive, with a number of companies offering a variety of products. Some of the major players in the market include Sanofi, GlaxoSmithKline, Merck, and Novartis. Other companies, such as CSL Behring, Teva Pharmaceuticals, and Mylan, also offer products in the Haegarda market. Show Less Read more